Avidea is leveraging innovations in polymer–drug conjugate (PDC) technologies to usher in an era of safer and more effective ‘precision immunotherapies.’
Many promising immunotherapies inadequately reach target tissues leading to dose-limiting toxicities and low efficacy. Avidea’s PDC platforms address this challenge by shielding drug molecules during transit through the body and targeting them to specific cells where activity is needed. What distinguishes Avidea’s PDCs is that each enables precise and truly unparalleled control over key parameters that affect safety, efficacy and manufacturability
for rapid hypothesis testing and hit-to-lead
with programmable, high drug loading (up to 60%m/m)
to specific tissue and cell populations not limited by antigen expression
for improved therapeutic index